Erlotinib Hydrochloride CAS 183319-69-9 Chiyero >99.0% (HPLC)

Erlotinib Hydrochloride (CAS: 183319-69-9) ndi kamolekyu kakang'ono ka epidermal growth factor receptor tyrosine kinase reversible inhibitor, yomwe imagwiritsidwa ntchito makamaka pochiza khansa ya m'mapapo yam'deralo kapena ya metastatic yosakhala yaying'ono yam'mapapo komanso njira yachiwiri kapena mizere itatu. khansa ya pancreatic.Erlotinib Hydrochloride idavomerezedwa mu Novembala, 2004, kuti azichiza khansa yapakhungu yapamwamba kapena ya metastatic yopanda maselo yaying'ono.Ndi m'gulu lomwelo la Gefitinib, quinazoline ina yovomerezeka kuti ichiritse khansa yapamwamba ya m'mapapo, koma yokhala ndi mankhwala abwino a pharmacokinetic.Molekyuyi idapangidwa ndi Pfizer ndipo chitukuko chinayambika mogwirizana ndi OSI, chomwe chinatenga ufulu wonse wa mankhwalawa pamene Pfizer adagwirizanitsidwa ndi Warner Lambert.Pambuyo pake, Genentech/Roche adachita mgwirizano ndi OSI kuti apange ndikugulitsa mankhwalawa ku US ndi Padziko Lonse.Selective epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitor.Antineoplastic.Erlotinib Hydrochloride ndi HER1/EGFR inhibitor yokhala ndi IC50 ya 2 nM.Erlotinib HCl imapezeka ngati mapiritsi a 25-, 100-, ndi 150-mg fororal administration.